Icu Medical Inc

This non-binding advisory proposal asks stockholders to approve the Company’s disclosed 2025 named executive officer compensation (the CD&A, Summary Compensation Table and related disclosures). Management seeks this vote to confirm alignment between executive pay and Company performance, citing a pay-for-performance philosophy that emphasizes performance-based cash and multi-year performance RSUs plus time-based RSUs to retain executives and align interests with stockholders. The Board notes prior strong support for its compensation program (approximately 96% in favor in 2025) and ongoing engagement with large stockholders to design compensation consistent with market practices. Although advisory and non-binding, the Compensation Committee will consider the vote outcome when setting future compensation. Key context includes the Company’s use of Adjusted EBITDA and Free Cash Flow metrics in annual incentives and PRSUs tied to multi-year Adjusted EBITDA and Adjusted Revenue targets, as well as severance/change-in-control provisions and governance safeguards (clawback policy, anti-hedging/pledging). The Board recommends a FOR vote because it believes the program drives long-term value creation, aligns management incentives with stockholder interests, and supports retention of key executives. Investors reviewing this proposal should weigh the Company’s demonstrated financial performance, the materiality of equity-based compensation, and the non-binding nature of the vote when assessing governance implications.

Proposal 4 asks stockholders to approve certificate amendments removing certain supermajority (two‑thirds) voting thresholds and replacing them with simple majority standards for actions such as shortening a director’s term, removing a director without cause, and increasing the size of the Board. Management frames this as a response to a 2025 stockholder vote and to stockholder engagement indicating preference for majority voting, and the Board concluded after weighing governance tradeoffs that elimination of these supermajority provisions is in the Company’s and stockholders’ best interests. Approving the amendment simplifies governance and aligns the Company with stockholder sentiment but also reduces structural protections that require broader consensus for certain governance changes. The Board will file the certificate amendment promptly if approved, and notes that Proposal 4 and Proposal 5 are independent (either may be implemented alone). For investors evaluating the proposal, key considerations include the Company’s ownership structure and whether removing supermajority thresholds materially affects protections against opportunistic transactions or concentrated shareholder actions; the Board asserts that the change better reflects current stockholder preferences and market practice.

Proposal 5 would amend the Certificate of Incorporation to permit stockholders holding 25% of the combined voting power to call a special meeting, subject to procedural safeguards in the Bylaws. Management frames the change as responsive to stockholder engagement and market practice and emphasizes the administrative and operational burden of special meetings; management argues 25% is high enough to ensure that only matters with broad stockholder support would prompt a special meeting while enabling a significant minority to convene one when necessary. The proposed Bylaw Amendments add procedural requirements for establishing record dates, disclosure of requested business and nominee information, and exclusions for duplicative or recently considered matters to reduce frictions and abuse. The Board will implement the amendment promptly if approved; it also states that if both Proposal 5 (25%) and the stockholder Proposal 7 (10%) pass, or if both receive sufficient votes, the Board will not implement the lower-threshold approach. For analysts evaluating governance impact, key considerations include the Company’s ownership concentration (notably several large institutional holders), the balance between stockholder empowerment and potential distraction from operations, and the practical thresholds used by peer companies.

Proposal 6 is a routine procedural measure seeking authorization to adjourn the meeting to continue proxy solicitations if there are not enough votes to approve Proposal 5 at the time of the meeting. Management argues this is in stockholders’ interests to allow additional outreach and voting time on a proposal that requires approval of a majority of outstanding shares; such adjournments are customary and limited to facilitating further solicitation rather than substantive changes to corporate governance.

This shareholder‑sponsored, precatory proposal seeks to lower the threshold for stockholder‑initiated special meetings to 10%, arguing that a lower threshold would empower shareholders to address perceived governance and performance failures (the proponent cites FDA actions, recalls, revenue declines, and securities investigations as evidence of underperformance). Management opposes the 10% threshold and instead proposes (Proposal 5) a 25% threshold with procedural safeguards in the Bylaws; the Board’s opposition centers on market practice data, concerns about misuse or disproportionate influence by small investor groups, administrative burden and distraction from operations, and the Company’s existing governance mechanisms and engagement. For analysts, the controversy turns on tradeoffs between stockholder empowerment and protection against opportunistic special meetings — key contextual factors include ICU’s ownership concentration (several institutional holders >5%), recent regulatory and operational issues referenced by the proponent, and the non-binding nature of the proposal (it is advisory). The Board recommends AGAINST the 10% proposal and FOR Proposal 5 (25% threshold).